Amicus Therapeutics Stock Analysis

FOLD Stock  USD 11.22  0.20  1.81%   
The main objective of Amicus Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Amicus Therapeutics is worth, separate from its market price. There are two main types of Amicus Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Amicus Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Amicus Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The Amicus Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Amicus Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Amicus Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Amicus Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Amicus Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.59. Amicus Therapeutics last dividend was issued on the 31st of August 2009. Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 496 people. To learn more about Amicus Therapeutics call John Crowley at 215 921 7600 or check out https://amicusrx.com.

Amicus Therapeutics Quarterly Cost of Revenue

9.95 Million

Amicus Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Amicus Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Amicus Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Amicus Therapeutics generated a negative expected return over the last 90 days
Amicus Therapeutics has high historical volatility and very poor performance
Amicus Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 329.23 M. Net Loss for the year was (236.57 M) with profit before overhead, payroll, taxes, and interest of 290.63 M.
Amicus Therapeutics currently holds about 386.84 M in cash with (166.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Over 99.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Amicus Q3 Loss Narrows, Galafold Sales View Updated - Nasdaq

Amicus Therapeutics Upcoming and Recent Events

Earnings reports are used by Amicus Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Amicus Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Amicus Largest EPS Surprises

Earnings surprises can significantly impact Amicus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-11-08
2023-09-30-0.08-0.070.0112 
2021-11-09
2021-09-30-0.17-0.19-0.0211 
2023-08-08
2023-06-30-0.12-0.15-0.0325 
View All Earnings Estimates

Amicus Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Amicus Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Amicus Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Amicus Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
8th of November 2023
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
5th of October 2023
Financial Statements and Exhibits. Termination of a Material Definitive Agreement
View
2nd of October 2023
Financial Statements and Exhibits. Regulation FD Disclosure. Unregistered Sales of Equity Securities. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Entry into a Material Definitive Agreement
View
28th of September 2023
Financial Statements and Exhibits. Regulation FD Disclosure
View
27th of September 2023
Financial Statements and Exhibits. Regulation FD Disclosure
View
21st of August 2023
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
15th of August 2023
Financial Statements and Exhibits. Regulation FD Disclosure
View
8th of August 2023
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Results of Operations and Financial Condition
View

Amicus Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.29 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amicus Therapeutics's market, we take the total number of its shares issued and multiply it by Amicus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Amicus Profitablity

Amicus Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Amicus Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Amicus Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Amicus Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Amicus Therapeutics' profitability requires more research than a typical breakdown of Amicus Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.47) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.15.
Last ReportedProjected for 2023
Return on Investment(35.01)(37.77)
Return on Average Assets(0.30)(0.33)
Return on Average Equity(1.42)(1.46)
Return on Invested Capital(0.32)(0.34)
Return on Sales(0.62)(0.67)

Management Efficiency

Amicus Therapeutics has return on total asset (ROA) of (0.0907) % which means that it has lost $0.0907 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3063) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of December 4, 2023, Return on Investment is expected to decline to -37.77. In addition to that, Return on Average Assets is expected to decline to -0.33. At present, Amicus Therapeutics' Current Assets are projected to increase significantly based on the last few years of reporting. . The current year's Assets Non Current is expected to grow to about 326.9 M, whereas Return on Average Assets are forecasted to decline to (0.33).
Last ReportedProjected for 2023
Book Value per Share 0.43  0.43 
Enterprise Value over EBIT(18.00)(18.47)
Enterprise Value over EBITDA(18.06)(18.53)
Price to Book Value 27.88  30.08 
Tangible Assets Book Value per Share 1.74  2.28 
Enterprise Value3.6 B3.1 B
Tangible Asset Value503.4 M556.9 M
The analysis of Amicus Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Amicus Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Amicus Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Dividend Yield
0.031
Forward Dividend Yield
0.031
Beta
0.865

Technical Drivers

As of the 4th of December, Amicus Therapeutics shows the Risk Adjusted Performance of (0.035592), mean deviation of 2.35, and Standard Deviation of 3.32. Amicus Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate thirteen technical drivers for Amicus Therapeutics, which can be compared to its rivals. Please confirm Amicus Therapeutics information ratio, as well as the relationship between the value at risk and kurtosis to decide if Amicus Therapeutics is priced correctly, providing market reflects its regular price of 11.22 per share. Given that Amicus Therapeutics has information ratio of (0.06), we suggest you to validate Amicus Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Amicus Therapeutics Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Amicus Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Amicus Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Amicus Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amicus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amicus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Amicus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Amicus Therapeutics Technical and Predictive Indicators

Amicus Therapeutics Forecast Models

Amicus Therapeutics' time-series forecasting models are one of many Amicus Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Amicus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Amicus Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Amicus Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Amicus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Amicus Therapeutics. By using and applying Amicus Stock analysis, traders can create a robust methodology for identifying Amicus entry and exit points for their positions.
Last ReportedProjected for 2023
Operating Margin(64.43)(69.52)
EBITDA Margin(0.61)(0.66)
Gross Margin 0.88  0.84 
Profit Margin(0.72)(0.77)

Current Amicus Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Amicus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Amicus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
17.78Buy9Odds
Amicus Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Amicus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Amicus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Amicus Therapeutics, talking to its executives and customers, or listening to Amicus conference calls.
Amicus Analyst Advice Details

Amicus Stock Analysis Indicators

Amicus Therapeutics stock analysis indicators help investors evaluate how Amicus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Amicus Therapeutics shares will generate the highest return on investment. By understating and applying Amicus Therapeutics stock analysis, traders can identify Amicus Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow249.5 M
Long Term Debt392 M
Common Stock Shares Outstanding289.1 M
Total Stockholder Equity123 M
Total Cashflows From Investing Activities92.3 M
Tax Provision-5.5 M
Property Plant And Equipment Net60.3 M
Warrants83 K
Cash And Short Term Investments293.6 M
Cash148.8 M
Accounts Payable15.4 M
Net Debt303.3 M
50 Day M A10.9862
Total Current Liabilities139 M
Other Operating Expenses533.7 M
Non Current Assets Total300.4 M
Forward Price Earnings60.6061
Common Stock Total Equity2.8 M
Non Currrent Assets Other14.3 M
Stock Based Compensation76.5 M
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.59)
Revenue Per Share
1.273
Quarterly Revenue Growth
0.267
Return On Assets
(0.09)
Return On Equity
(1.31)
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.